China Oncology ›› 2014, Vol. 24 ›› Issue (11): 808-813.doi: 10.3969/j.issn.1007-3969.2014.11.002

Previous Articles     Next Articles

Clinical significance of Sox17 gene promoter methylation in plasma circulating DNA in breast cancer patients

FU De-yuan1, REN Chuan-li2, TAN Hao-sheng1, WEI Jin-li1, ZHU Yu-xiang1, HE Chun-lan1,SHAO Wen-xi1, ZHANG Jia-xin1   

  1. 1.Department of Thyroid and Breast Surgery, Subei People’s Hospital of Jiangsu Province, Yangzhou Jiangsu 225001, China; 2.Medical Laboratory, People’s Hospital of Jiangsu Province, Yangzhou Jiangsu 225001, China
  • Online:2014-11-30 Published:2015-05-05
  • Contact: FU De-yuan E-mail: fdy1003@163.com

Abstract:

Background and purpose: Aberrant DNA methylation that leads to the inactivation of tumor suppressor genes plays important roles in development and progression of breast cancer. Clinically, related gene methylation is considered to be a promising biomarker for tumor diagnosis and prognosis. This study aimed to investigate the methylation status of Sox17 gene in breast cancer tissue and its corresponding plasma circulating DNA, as well as to investigate its value in breast cancer early diagnosis and prognosis. Methods: The Sox17 gene promoter methylation status was detected by MSP in 86 cases of breast cancer, 36 normal breast tissues and its paired plasma DNA, the results were analyzed with corresponding clinical and pathological features. Results: The frequency of Sox17 gene methylation rate among 86 breast cancer tissues was 77.9%(67/86), and was 61.6%(53/86)in plasma circulating DNA, however, no Sox17 gene methylation was found in normal breast tissues. Sox17 gene promoter methylation in plasma circulating DNA was significantly associated with the methylation status in tumor tissues (r=0.502, P=0.000). In breast cancer tissue specimens, Sox17 methylation status was significantly correlated with tumor stage (χ2=6.18, P=0.041) and lymph node metastasis (χ2=13.54, P=0.001); Sox17 gene methylation rate was significantly correlated with tumor stage (χ2=27.06, P=0.000), tumor size (χ2=9.65, P=0.007) and lymph node metastasis (χ2=20.80, P=0.000) in plasma samples, and there was no significant difference of Sox17 gene methylation between patient age, histological grade and ER, PR, HER-2/neu status. Conclusion: Sox17 gene promoter methylation plays an important role in the carcinogenesis and development of breast cancer, and may be associated with the prognosis of breast cancer. Furthermore, methylated Sox17 gene may be a useful tumor biomarker in plasma circulating DNA for breast cancer detection and disease monitoring.

Key words: span: , serif: " span="" circulating="" plasma="" dna="">Breast cancer, Sox17 gene, DNA methylation, Plasma circulating DNA